Fabry Disease Treatment Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Japan, China, India, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025

Fabry Disease Treatment Market size is projected to experience significant growth from 2019 to 2025.
 

The ongoing research and development for the treatment of Fabry disease, adoption of advanced technologies in the research practices are some of the factors that are driving the market growth. Rising number of patient base diagnosed with Fabry disease coupled with growing adoption of novel therapies that improves efficacy such as chaperone treatment is gaining a significant traction that in turn has propelled the market growth.
 

Growing demand for messenger RNA as a treatment modality for Fabry disease is boosting the market growth. The rising adoption of the treatment is mostly witnessed in the countries that have higher ratio of patients diagnosed with Fabry disease. For instance, according to the estimates provided by Census Bureau’s population, in the U.S. around 3,800 males are suffering from Fabry disease. Hence, the adoption of these novel treatments in order to mitigate or remove the disease is witnessing a significant market growth over the forecast period.
 

However, lack of awareness about advancements with respect to treatments for Fabry disease and limitations in adopting new technologies in certain countries owing to inadequate financial support from the respective government is hampering the adoption of the novel treatment and may hinder the market in the upcoming years.
 

The enzyme replacement therapy is currently dominating the market. Growing launches of new therapies that shows greater efficacy such as gene therapy are some of the factors that are gaining a significant traction and is expected to boost the market growth in the upcoming years.
 

North America is presently dominating the Fabry disease treatment market in the region. This is owing to the couple of factors such as advanced healthcare infrastructure, favorable reimbursement policies, and adoption of novel therapies are some of the factors driving the growth of the market in the region.
 

Asia Pacific is expected to witness the significant growth over the forecast period. This is owing to the growing opportunities for pharmaceutical companies due to growing healthcare spending.
 

Few of the key companies operating in Fabry disease treatment market include Sanofi S.A., Amicus Therapeutics Inc., Protalix Biotherapeutics Inc., ISU Abxis Co Ltd., Idorsia Pharmaceuticals Ltd., Avrobio Inc., JCR Pharmaceuticals Co Ltd., GlaxoSmithKline plc, Shire Plc., and Takeda Pharmaceutical Co. Ltd. key companies in the market are undergoing collaborations, and partnerships in order to gain maximum revenue share in the sector.
 

Fabry Disease Treatment Market by Treatment, 2014-2025 (USD Million)

• Enzyme Replacement Therapy
• Chaperone Treatment
• Substrate Reduction Therapy
• Others
• Food and beverage

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
• Latin America
  • Mexico
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia

Company Profiles:

• Sanofi S.A.
• Shire Plc.
• Amicus Therapeutics Inc.
• ISU Abxis Co Ltd.
• JCR Pharmaceuticals Co Ltd.
• Protalix Biotherapeutics Inc.
• Idorsia Pharmaceuticals Ltd.
• Avrobio Inc.
• GlaxoSmithKline plc
• Takeda Pharmaceutical Co. Ltd.

What Information does this report contain?